MX2019011404A - Receptor de antigeno quimerico. - Google Patents

Receptor de antigeno quimerico.

Info

Publication number
MX2019011404A
MX2019011404A MX2019011404A MX2019011404A MX2019011404A MX 2019011404 A MX2019011404 A MX 2019011404A MX 2019011404 A MX2019011404 A MX 2019011404A MX 2019011404 A MX2019011404 A MX 2019011404A MX 2019011404 A MX2019011404 A MX 2019011404A
Authority
MX
Mexico
Prior art keywords
antigen receptor
chimeric antigen
domain
target antigen
ganglioside
Prior art date
Application number
MX2019011404A
Other languages
English (en)
Inventor
Tamada Koji
Sakoda Yukimi
Ishizaki Hidenobu
Original Assignee
Noile Immune Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noile Immune Biotech Inc filed Critical Noile Immune Biotech Inc
Publication of MX2019011404A publication Critical patent/MX2019011404A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464442—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporciona un receptor de antígeno quimérico, que incluye una región de unión al antígeno blanco; una región transmembranal; y una región de transducción de la señal de activación de las células T, en la que el antígeno blanco es el gangliósido GM2.
MX2019011404A 2017-03-27 2018-03-26 Receptor de antigeno quimerico. MX2019011404A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017061461 2017-03-27
PCT/JP2018/012194 WO2018181207A1 (ja) 2017-03-27 2018-03-26 キメラ抗原受容体

Publications (1)

Publication Number Publication Date
MX2019011404A true MX2019011404A (es) 2020-02-05

Family

ID=63676179

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011404A MX2019011404A (es) 2017-03-27 2018-03-26 Receptor de antigeno quimerico.

Country Status (16)

Country Link
US (1) US20210122831A1 (es)
EP (1) EP3604344A4 (es)
JP (2) JP6761113B2 (es)
KR (1) KR102333377B1 (es)
CN (2) CN116874608A (es)
AU (1) AU2018242408B2 (es)
BR (1) BR112019019941B1 (es)
CA (1) CA3057811A1 (es)
CL (1) CL2019002715A1 (es)
IL (1) IL269515B2 (es)
MX (1) MX2019011404A (es)
RU (1) RU2770002C2 (es)
SG (1) SG11201908659RA (es)
TW (1) TWI753141B (es)
WO (1) WO2018181207A1 (es)
ZA (1) ZA201906321B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220033848A1 (en) * 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
CN110669144B (zh) * 2019-10-12 2021-09-17 华夏源（上海）细胞基因工程股份有限公司 一种靶向b细胞成熟抗原的嵌合抗原受体及其应用
CN110684739B (zh) * 2019-11-11 2022-05-27 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其应用
CN112608902B (zh) * 2020-12-21 2024-07-02 广东昭泰细胞生物科技有限公司 一种第四代car-t细胞及其应用
EP4352091A1 (en) * 2021-05-27 2024-04-17 Innovative Cellular Therapeutics Holdings, Ltd. Modified chimeric antigen receptor and use thereof
KR20240034205A (ko) 2021-07-16 2024-03-13 노일 이뮨 바이오테크 가부시키가이샤 항EGFRviii 항체, 폴리펩타이드, 상기 폴리펩타이드를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법 및 상기 폴리펩타이드를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터
TW202307009A (zh) 2021-07-16 2023-02-16 日商諾伊爾免疫生物科技股份有限公司 嵌合抗原受體、表現前述受體之細胞、含有前述細胞之醫藥組成物、前述細胞之製造方法、及含有編碼前述嵌合抗原受體之鹼基序列之聚核苷酸或載體

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4804697A (en) * 1996-10-04 1998-04-24 Human Genome Sciences, Inc. Therapeutic compositions and methods for treating disease states with leukocyte adhesion inhibitor-1 (lai-1), and chemokine beta-11 (ckbeta-11)
AU7449200A (en) * 1999-09-30 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Derivatives of antibody against ganglioside gm2
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2012033885A1 (en) 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
IN2014CN02906A (es) * 2011-10-20 2015-07-03 Us Health
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
SG11201504106XA (en) * 2012-12-06 2015-07-30 Univ Kanazawa Nat Univ Corp Therapeutic method for mesothelioma
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
PT3514172T (pt) * 2014-04-01 2020-04-21 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Imunorrecetores específicos de claudina-6 e epítopos de células t
US11041021B2 (en) * 2014-05-23 2021-06-22 University Of Florida Research Foundation, Incorporated Car based immunotherapy
CA2950763A1 (en) * 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
IL308324A (en) * 2014-09-19 2024-01-01 Hope City IL13RA2-targeted chimeric antigen receptor T cells
PT3205720T (pt) * 2014-10-09 2019-10-28 Univ Yamaguchi Vetor de expressão de car e células t que expressam car
KR20160056228A (ko) 2014-11-11 2016-05-19 주식회사 산내들 견과류의 껍질 분리 회수장치
MX2017012352A (es) * 2015-04-03 2018-01-26 Eureka Therapeutics Inc Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
CN114853873A (zh) * 2015-06-11 2022-08-05 格纳西尼有限公司 经修饰的白细胞介素-7蛋白及其用途
AU2016274989A1 (en) * 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
EP3320773B9 (en) * 2015-07-10 2023-10-11 Chugai Seiyaku Kabushiki Kaisha Mouse having human cd3 gene substituted for endogenous cd3 gene
JP2018526013A (ja) * 2015-09-01 2018-09-13 イネイト・テューマー・イミュニティ・インコーポレイテッドＩｎｎａｔｅ Ｔｕｍｏｒ Ｉｍｍｕｎｉｔｙ， Ｉｎｃ． 免疫または免疫抑制性サイトカインに対する抵抗性が増大した免疫細胞およびその使用
WO2017159736A1 (ja) * 2016-03-17 2017-09-21 国立大学法人山口大学 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター
AU2020406083A1 (en) * 2019-12-17 2022-06-16 Ose Immunotherapeutics Bifunctional molecules comprising an IL-7 variant

Also Published As

Publication number Publication date
CN110461881A (zh) 2019-11-15
CA3057811A1 (en) 2018-10-04
RU2019129917A3 (es) 2021-08-02
CN116874608A (zh) 2023-10-13
RU2770002C2 (ru) 2022-04-14
BR112019019941A2 (pt) 2020-04-28
WO2018181207A1 (ja) 2018-10-04
BR112019019941B1 (pt) 2023-12-05
SG11201908659RA (en) 2019-10-30
RU2019129917A (ru) 2021-04-28
ZA201906321B (en) 2021-02-24
EP3604344A1 (en) 2020-02-05
EP3604344A4 (en) 2021-01-06
JP2020120660A (ja) 2020-08-13
KR102333377B1 (ko) 2021-11-30
AU2018242408A1 (en) 2019-10-10
JP6761113B2 (ja) 2020-09-23
IL269515B2 (en) 2023-05-01
IL269515A (es) 2019-11-28
JPWO2018181207A1 (ja) 2020-02-27
KR20190132637A (ko) 2019-11-28
US20210122831A1 (en) 2021-04-29
CL2019002715A1 (es) 2020-01-17
AU2018242408B2 (en) 2022-08-04
TW201840587A (zh) 2018-11-16
IL269515B1 (en) 2023-01-01
NZ757552A (en) 2023-09-29
TWI753141B (zh) 2022-01-21
CN110461881B (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
MX2019011404A (es) Receptor de antigeno quimerico.
PH12018500766A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
EP3615567A4 (en) CHIMERA ANTIBODY / T-CELL RECEPTOR CONSTRUCTS AND USES THEREOF
MX2023006482A (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
IL274921A (en) BCMA-directed chimeric antigen receptor and uses thereof
EP3665271A4 (en) CELL TARGETING MEDIA BY A CHEMICAL ANTIGEN RECEPTOR
IL274617A (en) Chimeric antigen receptor-directed BCMA, chimeric antigen receptor-directed CD19, and combination therapies
EP3749346A4 (en) VARIABLE DOMAINS OF ANTIBODIES TARGETING THE NKG2D RECEIVER
EP3365364A4 (en) CHIMERIC ANTIBODY / T-CELL RECEPTOR CONSTRUCTS AND USES THEREOF
AU2016258174B2 (en) Prostate specific membrane antigen binding fibronectin type III domains
PH12019500552A1 (en) Antibody specifically binding to pd-1 and functional fragment thereof
EP3700925B8 (en) Novel t-cell receptor
EP3568406A4 (en) T-CELLS WITH EXPRESSION OF A CHIMERIC ANTIGEN RECEPTOR
EP3733839A4 (en) T-CELL MODIFIED BY ANTIBODY MODIFIED ANTIBODY ANTIGEN RECEIVER AND THEIR USES
EP3518944A4 (en) ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN
TN2019000082A1 (en) Antibody specifically binding to il-17a and functional fragment thereof
EP3773658A4 (en) KIR3DL3 USEFUL AS HHLA2 RECEPTOR, ANTI-HHLA2 ANTIBODIES AND THEIR USES
EP3752197A4 (en) NKG2D CHIMERIC ANTIGEN RECEPTORS
EP3835320A4 (en) BINDING OF CHEMERA ANTIGEN RECEPTOR TO HLA-DR, AND CAR-T CELL
EP3757133A4 (en) ISOLATED CHIMERIC ANTIGEN RECEPTOR, THIS MODIFIED T-CELL CONTAINED AND USES
EP3635099A4 (en) T-CELLS WITH EXPRESSION OF A CHIMERIC ANTIGEN RECEPTOR
EP3582779A4 (en) 5-PIECE HETEROCYCLES WITH DELTA OPIOID RECEPTOR MODULATING COMPOUNDS, METHOD FOR THE PRODUCTION AND USE THEREOF
EP3902838A4 (en) CD30 BINDING FRACTIONS, CHEMERA ANTIGEN RECEPTORS AND THEIR USES
MY180940A (en) Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor
EP3578650A4 (en) NEW T-LYMPHOCYTE RECEPTOR